Monday, January 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Biodefense Scientist Art Friedlander Nominated for Service Award

by Global Biodefense Staff
August 23, 2012

Dr. Arthur M. Friedlander, a senior scientist at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), is one of 33 finalists for the Samuel J. Heyman Service to America Medal. Friedlander directed the development of new and promising vaccines against anthrax and plague and generated recommendations for post-exposure treatment of anthrax to protect the public in the event of a bioterrorist attack.

The awards, sponsored by the nonprofit Partnership for Public Service, are given to outstanding federal employees who work behind the scenes to advance the health, safety and well-being of Americans. Medal recipients will be announced on September 13.

Friedlander, a finalist in the Homeland Security category, has spent his 32-year career unraveling the mysteries of anthrax and plague infection and developing effective vaccines and therapies for these biological threats of national importance.

According to Colonel Andrea Stahl, USAMRIID’s Deputy Commander, Friedlander’s contributions to the field began in the early 1980s. His work shed light on how anthrax toxins bind to and damage host cells, and led to the development of a cellular and molecular model that is currently being used to evaluate new vaccines and therapies.

Beginning in 1990, Friedlander’s research established the definitive evidence in animal models for effective post-exposure antibiotic treatment to prevent inhalational anthrax.  These studies had wide-ranging impact: They formed the basis for the Department of Defense’s preventive medicine policy for managing potential aerosol anthrax exposures; led to adoption of the same management recommendations by the Centers for Disease Control and Prevention; and resulted in Food and Drug Administration approval of a new antibiotic for post-exposure preventive treatment of the civilian community (Source: USAMRIID).

Friedlander also directed the USAMRIID research team that developed a new anthrax vaccine, which was shown to be highly protective in animal models of inhalational anthrax. That work led to the development of new anthrax vaccines that are currently in human clinical trials under the auspices of the National Institutes of Health. In addition, he led the research effort that culminated in the development of a new multicomponent plague vaccine at USAMRIID. This product, proven effective against pneumonic plague in animal models, also is currently in human clinical trials.

During his military career, Friedlander has served as Chief, Airborne Diseases; Chief, Department of Pathobiology; and Chief, Bacteriology.  In his current role as Senior Scientist, Friedlander provides consultation and guidance to the USAMRIID Commander, the U.S. Army Medical Research and Materiel Command leadership, and the Department of Defense’s Chemical and Biological Defense Program.

Tags: Animal ModelsLeadershipUSAMRIID

Related Posts

two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.
Health Security

Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.

December 7, 2022
Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.
Policy + Initiatives

Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.

December 7, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC